132 related articles for article (PubMed ID: 38425755)
1. Genetic insights into repurposing statins for hyperthyroidism prevention: a drug-target Mendelian randomization study.
Huang A; Wu X; Lin J; Wei C; Xu W
Front Endocrinol (Lausanne); 2024; 15():1331031. PubMed ID: 38425755
[TBL] [Abstract][Full Text] [Related]
2. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
3. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
[TBL] [Abstract][Full Text] [Related]
4. Association of HMGCR inhibition with rheumatoid arthritis: a Mendelian randomization and colocalization study.
Ma L; Du Y; Ma C; Liu M
Front Endocrinol (Lausanne); 2023; 14():1272167. PubMed ID: 38047111
[TBL] [Abstract][Full Text] [Related]
5. Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.
Xiao W; Li Y; Zhuang Z; Song Z; Wang W; Huang N; Dong X; Jia J; Liu Z; Zhao Y; Qi L; Huang T
Lipids Health Dis; 2024 Jun; 23(1):163. PubMed ID: 38831433
[TBL] [Abstract][Full Text] [Related]
6. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
He JY; Zhang X; Wang K; Lv WQ
J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
[TBL] [Abstract][Full Text] [Related]
7. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
Qiao L; Lv S; Meng K; Yang J
Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
[TBL] [Abstract][Full Text] [Related]
8. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
[TBL] [Abstract][Full Text] [Related]
9. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
[TBL] [Abstract][Full Text] [Related]
10. Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis.
Chen H; Zhou X; Hu J; Li S; Wang Z; Zhu T; Cheng H; Zhang G
Lipids Health Dis; 2023 Dec; 22(1):220. PubMed ID: 38082436
[TBL] [Abstract][Full Text] [Related]
11. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
Huang W; Xiao J; Ji J; Chen L
Elife; 2021 Dec; 10():. PubMed ID: 34866576
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study.
Li Z; Tian M; Jia H; Li X; Liu Q; Zhou X; Li R; Dong H; Liu Y
Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):197-206. PubMed ID: 37688479
[TBL] [Abstract][Full Text] [Related]
13. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study.
Zhao SS; Yiu ZZN; Barton A; Bowes J
JAMA Dermatol; 2023 Mar; 159(3):275-280. PubMed ID: 36696131
[TBL] [Abstract][Full Text] [Related]
14. Association between genetically proxied lipid-lowering drug targets, lipid traits, and amyotrophic lateral sclerosis: a mendelian randomization study.
Yan Z; Xu Y; Li K; Liu L
Acta Neurol Belg; 2024 Apr; 124(2):485-494. PubMed ID: 37889424
[TBL] [Abstract][Full Text] [Related]
15. Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study.
Tan Z; Hong J; Sun A; Ding M; Shen J
Front Endocrinol (Lausanne); 2023; 14():1301163. PubMed ID: 38107516
[TBL] [Abstract][Full Text] [Related]
16. Effect of statins on sepsis and inflammatory factors: A Mendelian randomization study.
Zhang K; Liu W; Liang H
Eur J Clin Invest; 2024 May; 54(5):e14164. PubMed ID: 38229409
[TBL] [Abstract][Full Text] [Related]
17. Thyroid dysfunction and risk of cutaneous malignant melanoma: a bidirectional two-sample Mendelian randomization study.
Dong H; Pan L; Shen Y; Xu Q; Hu J; Hu Z; Fei Y
Front Endocrinol (Lausanne); 2023; 14():1239883. PubMed ID: 38093968
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Role of Plasma Lipids and Statin Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
Almramhi MM; Finan C; Storm CS; Schmidt AF; Kia DA; Coneys R; Chopade S; Hingorani AD; Wood NW
Neurology; 2023 Oct; 101(17):e1729-e1740. PubMed ID: 37657941
[TBL] [Abstract][Full Text] [Related]
19. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
Liang Z; Zhao L; Lou Y; Liu S
QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
[TBL] [Abstract][Full Text] [Related]
20. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.
Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S
EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]